SCHEMBL4053161

SCHEMBL4053161

c1coc(-c2ccc3nc(-c4ccc5ccccc5c4)oc3c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.52
ESR1 P03372 2/20 0.52
ESR2 Q92731 2/20 0.52
UTRN P46939 6/20 0.49
GPR119 Q8TDV5 2/20 0.49
PGR P06401 1/20 0.48
CYP1A2 P05177 1/20 0.45
AHR P35869 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
HSD17B10 Q99714 3/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
CASP3 P42574 2/20 0.44
SENP7 Q9BQF6 2/20 0.44
SENP6 Q9GZR1 2/20 0.44
ADORA2A P29274 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4061714 0.87 ALOX5 (0.56) ALOX5ESR1ESR2GPR119NPC1
SCHEMBL4060159 0.86 UTRN (0.52) ALOX5ESR1ESR2UTRNGPR119
SCHEMBL4050933 0.84 ALOX5 (0.47) ALOX5GPR119TDP1NPC1RAB9A
SCHEMBL4056364 0.83 ALOX5 (0.58) ALOX5GPR119PGRNPC1RAB9A
SCHEMBL4059615 0.82 RAB9A (0.60) UTRNGPR119TDP1NPC1RAB9A
SCHEMBL4051901 0.82 NPC1 (0.62) ALOX5GPR119TDP1NPC1RAB9A
SCHEMBL4058272 0.82 RAB9A (0.56) ALOX5GPR119HDAC6TDP1NPC1
SCHEMBL4051830 0.82 RAB9A (0.55) ALOX5GPR119CYP1A2TDP1NPC1
SCHEMBL4059581 0.82 VSIR (0.54) ALOX5ESR1ESR2UTRNGPR119
SCHEMBL4054486 0.81 ESR1 (0.59) ESR1ESR2UTRNGPR119CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B ALOX5 1869/4885ESR1 1649/4885ESR2 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.